Integra Lifesciences Q2 EPS $0.71 Beats $0.57 Estimate, Sales $381.30M Beat $374.07M Estimate
Portfolio Pulse from Benzinga Newsdesk
Integra Lifesciences (NASDAQ:IART) reported Q2 earnings of $0.71 per share, beating the analyst consensus estimate of $0.57 by 24.56%. However, this is a 13.41% decrease from the same period last year. The company also reported quarterly sales of $381.30 million, beating the analyst consensus estimate of $374.07 million by 1.93%, but this is a 4.15% decrease from the same period last year.
July 27, 2023 | 4:29 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Integra Lifesciences reported better than expected Q2 earnings and sales, but both figures are down from the same period last year.
While Integra Lifesciences beat analyst estimates for Q2 earnings and sales, the fact that both figures are down year-over-year could have a neutral impact on the stock. Investors may be pleased with the beat, but concerned about the year-over-year decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100